Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q2 2025
Lexicon Pharmaceuticals (LXRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Lexicon Pharmaceuticals (LXRX) reported revenue of $28.9M for the second quarter 2025 (Q2 2025), up 18-fold from a year earlier and up 23-fold from the quarter before. Operating margin was 12.9%, net earnings $3.3M (11.3% of revenue).
Lexicon Pharmaceuticals, Q2 2025: revenue $28.9M (18× year over year), operating margin 12.9%, net earnings $3.3M, operating cash flow $17.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.9M | 23× | 18× |
| Operating profit | $3.7M | — | — |
| Net earnings | $3.3M | — | — |
| Operating cash flow | $17.0M | — | — |
What changed
Revenue was $28.9M in Q2 2025, up 1653% year over year and up 2187% from the previous quarter. License was the largest line at 95% of revenue. Product declined 18%.
Operating profit was $3.7M, a 12.9% margin (up 3373.8 points year over year). Total costs fell 56% while revenue rose 1653%. Net earnings were $3.3M. The effective tax rate was 0.0%.
Operating cash flow was $17.0M, 523% of net earnings. Non-cash charges added back $176K of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $10.4M.
Questions
What was Lexicon Pharmaceuticals' revenue in the second quarter 2025?
Lexicon Pharmaceuticals (LXRX) reported revenue of $28.9M for the second quarter 2025 (Q2 2025), up 18-fold from a year earlier and up 23-fold from the quarter before.
Was Lexicon Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $3.7M (12.9% of revenue) and net earnings $3.3M.